L'Occitane shares rise on report of potential Blackstone offer
By Sherry Qin
L'Occitane International's shares rose sharply after a report that Blackstone is considering a bid for the skincare company.
L'Occitane's shares (HK:973) gained 9.4% to 28.45 Hong Kong dollars in early Asian trade Tuesday, on track for its largest daily percentage gain since last May.
Private equity firm Blackstone (BX) has been conducting preliminary due diligence as it mulls a potential offer for the skincare company, Bloomberg reported, citing people familiar with the matter. Blackstone is also considering the possibility of teaming up with L'Occitane's billionaire chairman Reinold Geiger on a buyout, the report said.
L'Occitane didn't immediately respond to a request for comment by Dow Jones Newswires.
Plans for taking over L'Occitane are not new, as Geiger considered taking the company private last year. L'Occitane subsequently said it had been informed by the controlling shareholder on Sep. 3 that "it has decided not to proceed with the possible transaction," according to an exchange filing.
Geiger owns about 73% of L'Occitane International, which currently has a market capitalization of HK$41.95 billion (US$5.36 billion), according to FactSet.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-05-24 2154ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks